The GPA is a collaboration between three leading international organisations in world dermatology: International Federation of Psoriasis Associations (IFPA); International League of Dermatological Societies (ILDS); and International Psoriasis Council (IPC)
One of the key aims of the GPA is to inform on the worldwide epidemiology of psoriasis. This authoritative resource on psoriasis was first published in 2019.
The GPA will be updated annually, in global collaboration with our dermatologists and international organisations around the world.
Our first edition contains data on psoriasis prevalence in adults and children, healthcare data and personal stories told by people with psoriasis worldwide.
Future editions of the GPA will be expanded to include access to treatment, comorbidities and cost to society.
The GPA will maximise the value of epidemiological research into psoriasis by facilitating international collaboration and greater standardisation in study methodology whilst meeting the highest scientific standards for epidemiological data collection and estimation.
IFPA is a nonprofit organisation comprising psoriasis associations from around the world. IFPA unites psoriasis associations so that their global campaign for improved medical care, greater public understanding and increased research will improve the lives of people who live with psoriasis and psoriatic arthritis.
Officially founded in 1935, the International League of Dermatological Societies (ILDS) has been promoting skin health around the world for over 80 years. Its forerunner began in 1889 as the first of many World Congresses of Dermatology. Today, the ILDS represents dermatology at the highest level with over 170 Member Societies from more than 80 countries, we represent over 150,000 dermatologists.
IPC is a dermatology led, voluntary, global nonprofit organisation dedicated to innovation across the full spectrum of psoriasis through research, education and patient care. The mission of the IPC is to empower our network of global key opinion leaders to advance the knowledge of psoriasis and its associated comorbidities, thereby enhancing the care of patients worldwide.
Epidemiological research has the potential to add to our understanding of the
prevalence and incidence of psoriasis and its comorbid diseases, as well their
psychosocial and societal impact. However, previous studies on the epidemiology of
psoriasis have lacked standardisation in case-definition and methodology. This
thereby limits the value of geographic comparisons, and provides very limited data
on temporal comparisons of the prevalence of this serious, chronic
noncommunicable skin disease.
The mission of the GPA is to provide the common benchmark on the complete burden of psoriasis in all countries and regions throughout the world. The GPA will leverage existing data from publications and registries; where gaps are identified additional studies will be commissioned. The GPA is a longterm project that seeks to drive continuous improvement in the understanding of psoriasis and to uncover how it affects both the individual and society at large. Whilst the first edition of the GPA will focus on the incidence and prevalence of psoriasis, future additions will be expanded to include access to treatment, comorbidities and cost to society.
The Global Psoriasis Atlas project is delivered by the academic project staff based at The University of Manchester and University Medical Center Hamburg-Eppendorf
The University of Manchester’s research has real-world impact beyond academia. We are at the forefront of the search for solutions to some of the world’s most pressing problems, seeking to be a global force for positive change.
Research topics and expertise, which are present at the UKE in particular, have been identified in recent years. This increasing scientific focus is supported by the Faculty of Medicine and is reflected in the research centers and joint projects at national and European level.
The Global Psoriasis Atlas (GPA) is a joint project of the ILDS (International League of Dermatological Societies), IFPA (International Federation of Psoriasis Associations) and IPC (International Psoriasis Council).
The aim of GPA is to document and use global and regional health care data for psoriasis in order to identify the global burden of psoriasis.
"Atlas" means a database on health information related to different geographic zones, including facts on epidemiology, health care structures, processed and outcomes.
The GPA is based on the scientific methods on epidemiology and health services research.
The GPA is funded by pooled grants from dermatological societies, foundations and industry.
The GPA has been founded according to the WHO resolution from May 24th 2014 which recognised psoriasis as a serious not 'relevant' non-communicable disease.